<DOC>
	<DOCNO>NCT01654874</DOCNO>
	<brief_summary>This trial single-blind , cross-over design . Up three patient confirm metastatic prostate adenocarcinoma three healthy volunteer receive two dos 20.0 ( ± 3 ) mCi intravenously administer 99mTc MIP 1404 ( preparation A preparation B ) . Whole-body planar scintigraphic image acquire various time point day study drug administration . A pelvic SPECT/CT image acquire day study drug administration . Blood collect pharmacokinetic measurement follow study drug administration . Each participant receive initial study drug administration ( preparation A ) second study drug administration ( preparation B ) approximately 7 21 day later . A final follow-up visit occur approximately 2 - 3 week second study drug administration .</brief_summary>
	<brief_title>99mTc-MIP-1404 Imaging Prostate Cancer : Phase I Clinical Study Assess Image Quality Simplified Kit Formulation Compared Multi-step Preparation 99mTc-MIP-1404</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male age 21 year old . Ability provide sign informed consent willingness comply protocol requirement . Participants must agree use acceptable form birth control throughout study period . Participants must agree use condom period seven day study drug administration , engage sexual activity . Additional Inclusion Criteria Metastatic Prostate Adenocarcinoma Patients : Histologic diagnosis prostate cancer validate medical history ( pathology report , available ) . Evidence metastatic disease demonstrate documented abnormal bone scan , CT scan , MRI Karnofsky performance ≥ 60 Additional Inclusion Criteria Healthy Volunteers : PSA laboratory assessment within normal range ( PSA &lt; 4 ng/ml ) Normal finding digital rectal examination Hemoglobin hematocrit within normal range Received radioisotope within 5 physical half live radioisotope prior study enrollment Have medical condition circumstance , opinion Investigator , would significantly decrease chance obtain reliable data , achieve study objective , complete study and/or post dose followup examination Participant determine Investigator clinically unsuitable study Serum creatinine ≥ 2.0 mg/dl Total bilirubin ≥ 2.0 mg/dl Liver transaminases ≥ 1.5 x ULN Platelet count &lt; 100,000/mm3 Absolute neutrophil count ( ANC ) &lt; 2,000/mm3 Hematocrit &lt; 30 % hemoglobin &lt; 10 g/dl Additional Exclusion Criteria Metastatic Prostate Adenocarcinoma Patients : Have receive permanent prostate brachytherapy implant within last 3 month 103Pd implant ; 12 month 125I implant Have malignancy within past year , basal squamous cell carcinoma skin , diagnosis location define clinically control treat complete response</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>